Pemafibrate
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Parmodia |
Other names | K-13675 |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
Chemical and physical data | |
Formula | C28H30N2O6 |
Molar mass | 490.556 g·mol−1 |
3D model (JSmol) | |
| |
|
Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.[1]
In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.[2][failed verification]
References
[edit]- ^ Yamashita S, Masuda D, Matsuzawa Y (January 2020). "Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases". Current Atherosclerosis Reports. 22 (1): 5. doi:10.1007/s11883-020-0823-5. PMC 6978439. PMID 31974794.
- ^ Pemafibrate Archived 2018-02-05 at the Wayback Machine, pharmacodia.com